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Abstract: Fusarium is one of the most toxigenic phytopathogens causing diseases and
reduced agricultural productivity worldwide. Current chemical fungicides exhibit toxicity
against non-target organisms, triggering negative environmental impact, and are a danger
to consumers. In order to explore the chemical diversity of plants for potential antifungal
applications, crude extract and fractions from Monotes kerstingii were screened for their activity
against two multi-resistant Fusarium oxysporum strains: Fo32931 and Fo4287. Antifungal
activity was evaluated by the determination of minimum inhibitory concentration (MIC) by
broth dilution of fermentative yeasts using kinetic OD600 nm reading by a spectrophotometer.
The n-butanol fraction showed the best activity against Fo4287.
We screened eleven
previously reported natural compounds isolated from different fractions, and a stilbene–coumarin
5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-4,7-dimethoxy-3-methyl-2H-1-benzopyran-2-one (1) was the
most active compound against both strains. Compound 1 was employed as a nucleophile with a
selection of electrophilic derivatizing agents to synthesize five novel stilbene–coumarin analogues.
These semisynthetic derivatives showed moderate activity against Fo32931 with only prenylated
derivative exhibiting activity comparable to the natural stilbene–coumarin (1), demonstrating the key
role of the phenolic group.
Keywords:
Monotes kerstingii;
stilbene–coumarins

antifungal activity;
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semisynthesis;

1. Introduction
Fusarium is a cross kingdom fungal pathogen with a detrimental influence on the quality, quantity,
and profitability of agricultural production and simultaneously incurs opportunistic fungal infections
in humans which pose an increasing threat to public health. In agricultural crops, these phytopathogens
are persistent in avoiding plant defenses, resulting in diseases and quality losses that amount to
billions of US dollars annually [1,2]. The management of plants infected by Fusarium through the use
of chemical fungicides has proven to exhibit toxicity to non-target organisms, cause environmental
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damage, and present a danger to consumers. More than 100 species of Fusarium have been identified
among which ten species complexes are pathogenic to humans causing diseases such as onychomycosis,
endophthalmitis, as well as skin and musculoskeletal infections with immunocompromised patients
being mostly affected [3]. Highly invasive fusariosis is commonly related to hepatitis and meningitis
and is responsible for over one million new cases of blindness annually [4]. Additionally, clinically
relevant Fusarium species are resistant to almost all currently used antifungals including azoles,
echinocandins, and polyenes. There is a continuous need to search for new and efficient therapeutic
alternatives against this fungal pathogen from natural sources such as medicinal plants and to provide
an eco-friendly alternative to the use of pesticides [5,6]. It is estimated that approximately 25% of the
active pharmaceutical agents prescribed in the United States originate from plant sources [7]. Moreover,
natural products often possess more ‘drug-like’ features compared to molecules from combinatorial
chemistry alone in terms of functional groups, polarity, three-dimensionality, and architectural
diversity [8,9]. Therefore, the continued exploration of plants for lead compounds in combination with
synthetic chemistry to improve their properties is an important avenue towards identifying compounds
with potent antibacterial and antifungal properties. However, to reach the drug criterion, natural
active compounds are often modified to produce semisynthetic derivatives to improve both physical
and biological properties. Based on this approach, an antifungal drug, anidulafungin, was synthesized
from echinocandin B originally isolated from a natural source [8,10]. The antifungal potential of plant
extracts and fractions against Fusarium oxysporum has been explored in previous research [2,6,11].
As part of our ongoing search for novel antimicrobial and antifungal drug candidates from natural
sources [12–14], we undertook a phytochemical study of the leaf and stem of the African shrub
Monotes kerstingii, which led to the isolation of several specialized metabolites (Figure 1) [15]. Herein,
we report the antifungal activity of the crude extract, fractions, and natural specialized metabolites
from the stem bark of M. kerstingii against two Fusarium oxysporum strains: Fo32931, pathogenic to
humans, and Fo4287, pathogenic to plants. Chemical modifications were carried out on the most active
compound and the antifungal properties of the resultant semisynthetic derivatives were evaluated.
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Figure 1. Structures of specialized metabolites 1–11 isolated from Monotes kerstingii [15].

Figure 1. Structures of specialized metabolites 1–11 isolated from Monotes kerstingii [15].
Table 1. Minimum inhibitory concentration (MIC) of crude extracts, fractions, as well as natural and
hemisynthetic pure compounds against Fo32931 and Fo4287.
Type

Code

Fo32931
MIC (µg/mL)

Fo4287
MIC (µg/mL)

Extract

MKS
MKSHEX
MKSEA
MKSBUT
1a

841
>1000
>1000
448
477

679
331
171
23
>1000

Fractions
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2. Results and Discussion
2.1. Antifungal Activity of Crude Extract, Fractions, and Specialized metabolites from Monotes kerstingii
against Fo32931 and Fo4287
Crude extract from M. kerstingii stem bark (MKS) together with hexane (HEX), ethyl acetate (EA),
and n-butanol (BUT) fractions (MKSHEX, MKSEA, and MKSBUT) were screened for their antifungal
activity against two F. oxysporum strains: Fo32931, pathogenic to humans, and Fo4287, pathogenic to
plants (Table 1). Their antifungal activity was evaluated by cell growth curves. Potato dextrose broth
(PDB) was used as a negative control and nystatin with an inhibitory concentration of 50 µg/mL was
used as a positive control (Figure S1). The resultant minimum inhibitory concentration (MIC) was
classified as strong (<100 µg/mL), moderate (100–500 µg/mL), weak (500–1000 µg/mL), or inactive
(>1000 µg/mL) [16]. The crude extract, MKS, showed weak activity against both strains. MKSHEX
exhibited moderate activity against Fo4287 with a MIC of 331 µg/mL but was inactive against Fo32931.
MKSEA was totally inactive against Fo32931 and moderately active against Fo4287 (MIC = 171 µg/mL).
Strikingly, MKSBUT was strongly active against Fo4287 with an MIC of 23 µg/mL, which is two
times more than nystatin, the positive control (MIC = 50 µg/mL), but moderately active against
Fo32931 (MIC = 448 µg/mL). The presence of active compounds in the n-butanol suggests that active
fractions/compounds against Fusarium spp. are more typically polar than non-polar. This result is
in accordance with those recently published by Khan et al. (2018) and Nefzi et al. (2017), and it
demonstrates the highest activity of n-butanol fraction compared to other less polar fractions [17,18].
Table 1. Minimum inhibitory concentration (MIC) of crude extracts, fractions, as well as natural and
hemisynthetic pure compounds against Fo32931 and Fo4287.
Type

Code

Fo32931
MIC (µg/mL)

Fo4287
MIC (µg/mL)

Extract

MKS

841

679

Fractions

MKSHEX
MKSEA
MKSBUT

>1000
>1000
448

331
171
23

Hemisynthetic

1a
1b
1c
1d
1e

477
281
103
708
341

>1000
658
>1000
>1000
621

Natural

1
2
3
4
5
6
7
8
9
10
11

116
337
327
553
98
116
408
174
473
>1000
523

96
286
330
273
180
361
915
457
>1000
>1000
>1000

Pop

Nystatin

50

50

MKS: M. kerstingii stem bark; MKSHEX: M. kerstingii hexane fraction; MKSEA: M. kerstingii ethyl acetate fraction;
MKSBUT: M. kerstingii n-butanol fraction. Strong/good activity (MIC: <100 µg/mL); moderate activity (MIC:
100–500 µg/mL); weak activity (MIC: 500–1000 µg/mL); no activity (MIC: >1000 µg/mL) [16].

Eleven natural compounds which were isolated from the above-mentioned fractions were screened
for their antifungal activity against both Fo32931 and Fo4287 including two stilbene–coumarins (1, 2),
a stilbene (3), a coumarin (4), two ellagic acid derivatives (5, 6), three steroids (7–9), a triterpene (10),
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and a cinnamate (11) (Figure 1). Compounds 2, 7, and 9–11 were isolated from the n-hexane fraction;
1–5 and 8 from the ethyl acetate fraction; and 1 and 6 from the n-butanol fraction [15]. In general,
the pure compounds were more active against Fo32931 where eight were moderately active, two weakly
active, and one inactive. Against Fo4287, one compound exhibited marginally strong activity, six were
moderately active, one weakly active, and three inactive (Table 1). The overall results of the pure
compounds demonstrate a strain-dependent variation where the plant pathogen strain Fo4287 was
more resistant to M. kerstingii-specialized metabolites than the human pathogen strain, Fo32931.
The stilbene–coumarin (1)—5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-4,7-dimethoxy-3-methyl-2H-1
-benzopyran-2-one—was the most actively tested compound with marginal strong activity against
Fo4287 (MIC = 96 µg/mL) and Fo32931 (MIC = 116 µg/mL). Compound 2, a natural alkylated derivative
of (1) at C-3 of the coumarin ring showed moderate activity in both strains, demonstrating the
importance of the free hydrogen H-3 of the double bond ∆3,4 in the antifungal activity of compound
1 against F. oxsporum. In comparison to compound 1, the monomers stilbene (3) and coumarin (4)
displayed reduced activity (Table 1). This was in accordance with the previously published results by
Montagner et al. (2008) and Wu et al. (2008) who demonstrated the antifungal effect of coumarins
against various fungal strains including F. oxysporum [19,20]. Ellagic acid (5) and its derivative (6)
had marginally strong activity against Fo32931 with a MIC of 98 µg/mL and 116 µg/mL, respectively,
and exhibited strain-dependent activity with moderate reduced activity towards Fo4287 (180 µg/mL
and 361 µg/mL). Ellagic acid and ellagitannins have also been identified as active principles of
pomegranate peel extract against Fusarium wilt of tomato plants [21]. The steroid 7 and its acylated
derivative 9, both isolated from the hexane fraction, showed moderate activity against Fo32931 but
were inactive against Fo4287. This result is consistent with data obtained by Mbambo et al. (2012) on
Fusarium verticilloides for the same class of compounds [22]. Interestingly, compound 8, a glycosylated
derivative of 7, exhibited significant increased activity two times greater the activity of compound 7
against both strains. It is postulated that after hydrolysis of the glycosylated compound, the glucose
is absorbed and subsequently inhibits hyphal growth of yeast. The fungicidal action of the sugar
unit is due to the effect on cell wall synthesis by inhibiting β-1,3-D-glucan synthase in fungal cell
membranes [23,24]. The triterpene (10) and cinnamate (11) were weakly or inactive against both strains.
Considering the interactions between compounds in different fractions and their effects on
antifungal activity, it is observed that MKSHEX was moderately active against Fo4287, whilst the
pure compounds 7, 9–11 isolated from this fraction were inactive on this strain (with exception of
2 which was moderately active), demonstrating their synergistic effect against Fo4287 or an as yet
unidentified compound is responsible for the apparent activity. On the other hand, MKSHEX was
inactive against Fo32931, but the above-mentioned pure compounds individually were moderately
active, demonstrating an antagonistic effect in this fraction against Fo32931. Similarly, although
MKSEA was totally inactive against Fo32931, the majority of compounds 2–4 and 8, isolated from this
fraction, were moderately active against this strain. In addition, the most active compounds 1 and 5
were isolated from the ethyl acetate fraction. Similar results demonstrating the weak activity of the
hexane and ethyl acetate fractions of plant extracts were obtained by Ahmad et al., 2011, and Sunita
et al., 2012 [25,26]. Finally, the strong antifungal activity of the n-butanol fraction on Fo4287 could
be explained by the co-presence of compounds 1 and 6 having a synergistic effect in that fraction.
Our results show a strain-dependent variation where, in general, the crude extract and fractions had
greater efficacy towards Fo4287, whereas for Fo32931, the results clearly demonstrate that activity
increases with compound purity.
2.2. Alkylation of Compound 1: Semisynthesis of Allylated, Propargylated, Prenylated, and Benzylated
Derivatives 1a–e
Having identified the natural stilbene–coumarin (1), a compound with marginal strong MIC
against both strains, a number of analogues of 1 were synthesized with an objective to improve its
inhibitory activity. As phenolic groups have previously been demonstrated to exhibit antifungal
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Scheme1.1. Synthesis
Synthesis of semisynthetic compounds

2.2.1.
2.2.1.Characterization
Characterizationof
ofCompounds
Compounds 1a–e
1a–e
The structures of the semisynthetic derivatives were established from spectral data, mainly
HR-ESI-MS, 1D and 2D NMR, and by comparison with literature data.
Compound 1a is a white amorphous solid soluble in chloroform. The HR-ESI-MS spectrum
showed a pseudo molecular ion peak [M + H]+ at m/z 365.1427 (calcd. for C22 H21 O5 + , 365.1389)
corresponding to the molecular formula C22 H20 O5 with 13 degrees of unsaturation. The IR absorption
spectrum of 1a showed the characteristic bands at 1729, 1603, 1509, and 1257 cm−1 , respectively,
ascribed to a carbonyl group, ethylenic and aromatic double bonds, and ether functionality [29].
Its 1 H NMR spectrum (Table 2) in conjunction with 13 C NMR [15,30] in which trans-ethylenic protons
were observed at δH /δC 6.70 (d, J = 16.0 Hz, 1H)/131.4 and 7.68 (d, J = 16.0 Hz, 1H)/126.7; an AA’BB’
system of a para-substituted aromatic ring at δH /δC 6.83 (d, J = 8.7 Hz, 2H)/115.1 and δH /δC 7.35
(d, J = 8.7 Hz, 2H)/127.9, while the AB system of two aromatic protons H-6 and H-8 resonated at δH /δC
6.87 (d, J = 2.3 Hz, 1H)/111.7 and δH /δC 6.66 (d, J = 2.3 Hz, 1H)/100.0. The two methoxy groups at
C-4 and C-7 were observed as singlets at δH /δC 3.88/56.3 and 3.80/55.7, respectively. The absence
of a broad absorption band on the IR spectrum of 1a for the OH group at around 3300–3500 cm−1
suggested a substitution at C-4”. This was confirmed by the presence of the signals of an oxyallyl
group [31] on the 1 H and 13 C NMR of 1a as a doublet of an oxymethylene at δH 4.50 (J = 2.6 Hz,
H-1000 )/68.9; a multiplet at δH 5.99 (H-2000 ); and a set of two diastereotopic protons of an exomethylene
carbon at δH 5.36 dd (J = 1.5 and 17.3 Hz) and δH 5.24 d (J = 11.8 Hz). The location of the
allyl group at C-400 was confirmed by the HMBC correlation (Figure 2) between the oxymethylene
protons at δH 4.50 and C-400 at δC 157.5. Based on this evidence, compound 1a was identified as
5-[(1E)-2-(4-prop-2-enyloxyphenyl)ethenyl]-4,7-dimethoxy-3-2H-1-benzopyran-2-one.
Similarly, the synthesized compound 1b was obtained as white amorphous solid soluble in
chloroform. Its molecular formula was established as C22 H18 O5 by the interpretation of its HR-ESI-MS
(positive mode) showing the protonated molecular ion peak [M + H]+ at m/z 363.1268 (calcd. for
C22 H19 O5 + , 363.1232). Its IR spectrum showed signals of a triple bond at 2129 cm−1 , C=O at 1715 cm−1 ,
C=C at 1600 and 1508 cm−1 , as well as C-O-C at 1247 and 1152 cm−1 . The 1 H and 13 C NMR spectra of
1b showed high similarity with those of 1a (Tables 2 and 3) suggesting that 1b is a stilbene–coumarin
with the same skeleton as 1a. However, the signals of the oxyallyl group in 1a were replaced by those
of an oxypropargyl group in 1b, most notably a doublet at δH 2.48 (d, J = 2.4)/75.7 characteristic of the
methine proton H-3000 of a propargyl group. In the 13 C spectrum, C-1000 and C-2000 appeared at 55.9 and
78.4 ppm, respectively, in accordance with literature data [32,33]. The location of this substituent at
C-4” was confirmed by the analysis of the HMBC spectrum of 1b on which clear correlations were
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observed between H-1000 at δH 4.66 ppm and C-4” at δC 157.5 ppm (Figure 2). Compound 1b was thus
identified as 5-[(1E)-2-(4-prop-2-ynyloxyphenyl)ethenyl]-4,7-dimethoxy-3-2H-1-benzopyran-2-one.
Table 2. 1 H NMR data of compounds 1a–e [CDCl3 ; 500 MHz].
N◦

Compound 1a
δH (m, J in Hz)

Compound 1b
δH (m, J in Hz)

Compound 1c
δH (m, J in Hz)

Compound 1d
δH (m, J in Hz)

Compound 1e
δH (m, J in Hz)

3
4
5
6
7
8
9
10
10
20
100
200 , 600
400
300 , 500
1000
2000

5.49 (1H, s)
6.87 (1H, d, 2.6)
6.66 (1H, d, 2.5)
7.68 (1H, d, 16.0)
6.70 (1H, d, 16.0)
7.35 (2H, d, 8.7)
6.86 (2H, d, 8.7)
4.50 (2H, d, 2.6)
5.99 (1H, m)
5.36 (1H, dd, 17.3;
1.5)
5.24 (1H, d, 11.8)

5.52 (1H, s)
6.89 (1H, d, 2.4)
6.68 (1H, d, 2.6)
7.71 (1H, d, 16.0)
6.73 (1H, d, 16.0)
7.39 (2H, d, 8.6)
6.93 (2H, d, 8.8)
4.66 (2H, d, 2.4)

5.49 (1H, s)
6.87 (1H, d, 2.6)
6.65 (1H, d, 2.6)
7.67 (1H, d, 15.9)
6.71 (1H, d, 15.9)
7.35 (2H, d, 8.7)
6.85 (2H, d, 8.7)
4.46 (2H, d, 6.7)
5.43 (1H, t, 2.7)

5.51 (1H, s)
6.89 (1H, d, 2.6)
6.67 (1H, d, 2.6)
7.69 (1H, d, 16.0)
6.73 (1H, d, 16.0)
7.35 (2H, d, 8.8)
6.92 (2H, d, 8.8)
5.04 (2H, s)

5.62 (1H, s)
6.99 (1H, d, 2.5)
6.79 (1H, d, 2.5)
7.80 (1H, d, 15.9)
6.81 (1H, d, 15.9)
7.47 (2H, d, 8.7)
6.99 (2H, d, 8.7)
5.09 (2H, s)

3000

2.48 (1H, d, 2.4)

4000
5000
20000 , 60000
30000 , 50000
40000
4-OMe
7-OMe
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1.73 (3H, s)
1.68 (3H, s)
7.25–7.40 m
3.88 (3H, s)
3.80 (3H, s)

3.92 (3H, s)
3.89 (3H, s)

3.87 (3H, s)
3.80 (3H, s)

3.90 (3H, s)
3.82 (3H, s)

7.35 (2H, d, 8.5)
7.55 (2H, d, 8.5)
3.99 (3H, s)
3.92 (3H, s)

7 of 14

COSY and
and HMBC
HMBC correlations
correlations of compounds 1a–e.
Figure 2. COSY

Compound 1c was obtained as white leaf solid soluble in chloroform. The HR-ESI-MS spectrum
(positive mode) of 1c showed the protonated molecular ion peak [M + H]+ at m/z 393.1716 (calcd.
C24H25O5+, 393.1702) compatible with the molecular formula C24H24O5 with 13 degrees of unsaturation.
As with 1a and 1b, compound 1c showed characteristic signals of the stilbene–coumarin skeleton
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Table 3.

13 C

NMR data of compounds 1a–e [CDCl3 ; 125 MHz].

N◦

Compound 1a
δC (m)

Compound 1b
δc (m)

Compound 1c
δc (m)

Compound 1d
δc (m)

Compound 1e
δc (m)

2
3
4
5
6
7
8
9
10
10
20
1”
2”, 6”
4”
3”, 5”
1000
2000
3000
4000
5000
10000
20000
30000
40000
50000
60000
4-OMe
7-OMe

162.1 (s)
88.2 (d)
169.2 (s)
131.0 (s)
111.7 (d)
162.9 (s)
100.0 (d)
156.4 (s)
106.7 (s)
126.7 (d)
131.4 (d)
138.8 (s)
127.9 (d)
157.5 (s)
115.1 (d)
68.9 (t)
133.1 (d)
117.4 (t)

162.1 (s)
88.2 (d)
169.2 (s)
131.0 (s)
111.9 (d)
162.9 (s)
100.1 (d)
156.4 (s)
106.7 (s)
127.2 (d)
131.2 (d)
138.8 (s)
115.2 (d)
157.5 (s)
127.9 (d)
55.9 (t)
78.4 (s)
75.7 (d)

162.1 (s)
88.2 (d)
169.3 (s)
130.0 (s)
111.7 (d)
162.9 (s)
100.0 (d)
156.4 (s)
106.7 (s)
126.5 (d)
131.4 (d)
138.9 (s)
127.9 (d)
158.9 (s)
115.0 (d)
64.9 (t)
119.5 (d)
138.4 (s)
25.9 (q)
18.2 (q)

162.0 (s)
88.0 (d)
169.2 (s)
130.2 (s)
111.6 (d)
162.8 (s)
100.0 (d)
156.4 (s)
106.6 (s)
126.7 (d)
131.3 (d)
138.9 (s)
127.9 (d)
158.7 (s)
115.1 (d)
70.0 (t)

162.1 (s)
88.2 (d)
169.2 (s)
130.5 (s)
111.8 (d)
162.9 (s)
100.1 (d)
156.5 (s)
106.7 (s)
127.0 (d)
131.3 (d)
138.9 (s)
128.0 (d)
158.5
115.2 (d)
69.3

136.7 (s)
128.6 (d)
127.9 (d)
128.0 (d)
127.9 (d)
128.6 (d)
56.4 (q)
55.7 (q)

135.9
129.0
131.8
129.0
131.8
122.0
56.4
55.7

56.3 (q)
55.7 (q)

56.4 (q)
55.7 (q)

56.3 (q)
55.7 (q)

Spectroscopic data of compounds 1a–e. 5-[(1E)-2-(4-prop-2-enyloxyphenyl)ethenyl]-4,7-dimethoxy-3-2H-1benzopyran-2-one (1a) White amorphous solid; IR (KBr) νmax (cm−1 ): 1729 (C=O), 1603 and 1509 (C=C),
1380 (Csp3 -H), 1257 and 1150 (C-O); 1 H, 13 C NMR, see Tables 1 and 2; HR-ESI-MS: m/z 365.1427 [M + H]+ (calcd.
for C22 H21 O5 + , 365.1389). 5-[(1E)-2-(4-prop-2-ynyloxyphenyl)ethenyl]-4,7-dimethoxy-3-2H-1-benzopyran-2-one
(1b) White amorphous solid; IR (KBr) νmax (cm−1 ): 2129 (C≡C), 1715 (C=O), 1600 and 1508 (C=C), 1378 (Csp3 -H),
1247 and 1152 (C-O); 1 H, 13 C NMR, see Tables 1 and 2; HR-ESI-MS: m/z 363.1268 [M + H]+ (calcd. for
C22 H19 O5 + , 363.1232). 5-[(1E)-2-(4-prenyloxyphenyl)ethenyl)]-4,7-dimethoxy-3-2H-1-benzopyran-2-one (1c)
White leaf solid; IR (KBr) νmax (cm−1 ): 1731 (C=O), 1603 and 1508 (C=C), 1381 (Csp3 -H), 1251 and 1149
(C-O); 1 H, 13 C NMR, see Tables 1 and 2; HR-ESI-MS: m/z 393.1716 [M + H]+ (calcd. C24 H25 O5 + , 393.1702).
5-[(1E)-2-(4-benzyloxyphenyl)ethenyl)]-4,7-dimethoxy-3-2H-1-benzopyran-2-one (1d) White amorphous solid;
IR (KBr) νmax (cm−1 ): 1734 (C=O), 1602 and 1510 (C=C), 1385 (Csp3 -H), 1256 and 1153 (C-O); 1 H and
13 C NMR, see Tables 1 and 2; HR-ESI-MS: m/z 415.1544 [M + H]+ (calcd.
C26 H23 O5 + , 415.1545).
5-[(1E)-2-(4-bromobenzyloxyphenyl)ethenyl)]-4,7-dimethoxy-3-2H-1-benzopyran-2-one (1e) White amorphous
solid; IR (KBr) νmax (cm−1 ): 1731 (C=O), 1606 and 1510 (C=C), 1382 (Csp3 -H), 1256 and 1152 (C-O), 819 (C-Br);
1 H and 13 C NMR, see Tables 1 and 2; HR-ESI-MS: m/z 493.0652 [M + H]+ (calcd. C H BrO + , 493.0651).
26 22
5

Compound 1c was obtained as white leaf solid soluble in chloroform. The HR-ESI-MS spectrum
(positive mode) of 1c showed the protonated molecular ion peak [M + H]+ at m/z 393.1716 (calcd.
C24 H25 O5 + , 393.1702) compatible with the molecular formula C24 H24 O5 with 13 degrees of unsaturation.
As with 1a and 1b, compound 1c showed characteristic signals of the stilbene–coumarin skeleton
(Tables 2 and 3). Further analysis of the 1 H and 13 C NMR of 1c revealed the presence of an
oxyprenyl group at C-4” [34,35] characterized by two singlets of three protons each at δH/C 1.73/25.9
and 1.68/18.2 ascribed to the vinylic methyl groups; a triplet (J = 2.7 Hz) integrating as one
proton assigned to the vinylic proton H-2000 at δH 5.43, while the oxymethylene H-1000 resonated
as a doublet (J = 6.7 Hz) at δH 4.46. The presence of this substituent which was located at
C-4” (Figure 2) was confirmed the 13 C spectrum of 1c (Table 3). Compound 1c was identified
as 5-[(1E)-2-(4-prenyloxyphenyl)ethenyl)]-4,7-dimethoxy-3-2H-1-benzopyran-2-one.
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Compound 1d was obtained as white amorphous solid soluble in chloroform. Its molecular
formula was deduced as C26 H22 O5 by the interpretation of its HR-ESI-MS (positive mode) showing
the protonated molecular ion peak [M + H]+ at m/z 415.1544 (calcd. C26 H23 O5 + , 415.1545). Its IR
spectrum showed important bands at 1734, 1602, 1510, 1256, and 1153 cm−1 attributed to carbonyl, ethyl,
and aromatic double bonds and ether functions [35]. 1 H and 13 C NMR spectra and data (Tables 2 and 3)
of 1d were similar to the previously described derivatives. In addition, the 1 H NMR spectrum of 1d
showed, in addition to the signals of the aromatic protons of the stilbene–coumarin, another set of five
aromatic protons as multiplets between 7.25 and 7.40 ppm. This information combined with the presence
of a highly deshielded oxymethylene (H-1000 ) as a singlet at δH/C 5.04/70.0 suggested the presence of a
benzyl group [36] in compound 1d. HMBC correlation (Figure 2) between the oxymethylene proton
H-1000 and C-4” at δC 158.7 confirmed its location at C-4” of the stilbene–coumarin. Compound 1d was
identified as 5-[(1E)-2-(4-benzyloxyphenyl)ethenyl)]-4,7-dimethoxy-3-2H-1-benzopyran-2-one.
Compound 1e was obtained as white amorphous solid soluble in chloroform. Its molecular
formula was established as C26 H21 BrO5 based on its HR-ESI-MS spectrum (positive mode) on which
the pseudomolecular ion peak [M + H]+ was observed at m/z 493.0652 (calcd. C26 H22 BrO5 + , 493.0651).
The presence of a bromine atom in compound 1e was confirmed by two peaks with a 1:1 ratio in
the molecular ion region. Moreover, the IR spectrum displayed, in addition to the bands of 1c,
a characteristic band of C-Br at 819 cm−1 [37]. The NMR data (Table 2) were very similar to those of
1d confirming a stilbene–coumarin moiety bearing a benzyl group, however, contrary to multiplets
observed in the aromatic region between 7.25 and 7.40 ppm and assigned to a phenyl ring of the benzyl
group. The 1 H NMR spectrum of 1e displayed an AA’BB’ system of a para-bromodisubstituted aromatic
ring at δH/C [7.35 (2H, d, J = 8.5)/129.0 and 7.55 (2H, d, 8.5)/131.8]. The location of the para-bromobenzyl
group was confirmed at C-4” by the HMBC correlation between the oxymethylene H-1000 at δH 5.09
and C-4” at 158.5. Based on this evidence, the structure of compound 1e was established to be
5-[(1E)-2-(4-bromobenzyloxyphenyl)ethenyl)]-4,7-dimethoxy-3-2H-1-benzopyran-2-one.
2.2.2. Antifungal Activity of Semi-Synthetic Derivatives against Fo32931 and Fo4287
The semisynthetic derivatives (1a–e) were also assayed for their antifungal activity against F.
oxysporum strains. The compounds exhibited moderate activity towards Fo32931 which was contrary
to the weak to no activity against Fo4287 (Table 1). Inhibitory activity against Fo32931 clearly indicates
the influence of distinct chemical groups to antifungal activity. In detail, the prenylated derivative
1c was the most active semisynthetic derivative (MIC = 103 µg/mL) with comparable activity to the
most active natural compound 1 (MIC = 116 µg/mL), indicative of the importance of prenylation on
antimicrobial activity. The addition of prenyl groups to molecules has been demonstrated to play a
key role in antimicrobial activity as it increases the lipophilicity of the molecule, enhancing access,
affinity, and interaction with the lipophilic membrane or by inhibiting RAS transduction [38–40].
Compounds 1a,b and e exhibited moderate activity against Fo32931 with a MIC of 250–500 µg/mL.
Notably, bromination at the para position of the benzyl group in 1e significantly increases the activity
against both strains as compared only to the benzylated derivative compound 1d that had weak activity
(Scheme 1). As the semisynthetic compounds were in general less active than (1), it can be postulated
that the phenolic group plays a key role in the antifungal activity of specialized metabolites against
F. oxysporum. Phenolic-OH moiety increase hydrophilicity enhancing the ability of penetration and
damaging yeast plasma membrane to achieve high antifungal activity [41].
3. Materials and Methods
3.1. General Methods
IR spectra were recorded on KBr discs using a Perkin Elmer Spectrum 100 FT-IR-410 spectrometer;
ν in cm-1 .1 H-, 13 C-NMR, DEPT, COSY, HSQC, NOESY, and HMBC spectra: Bruker AMX 500 instrument
(at 500 and 125 MHz, respectively); in chloroform-d; δ in ppm rel. to Me4 Si as internal standard, J in Hz.
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HR-ESI-MS APEXIII (Bruker Daltonik) 7 Tesla (ESI-FT-ICR-MS); in m/z. Spectra were processed using
the computer software MestreNova 9.1. Column chromatography (CC) was performed over Merck
silica gel 60, particle size between 0.043 and 0.063 mm in diameter, and porosity 230–400 mesh ASTM.
Evaporation was performed using a BUCHI rotary evaporator under reduced pressure. Plant materials,
extracts, and fractions were weighed on a Satorius OT12 electronic mass balance. Pure compounds or
fractions were weighed on a Satorius BP221S electronic balance maximum rating 220 g d = 0.1 mg.
Analytical TLCs were carried out on pre-coated silica gel 60 F254 aluminum sheets (0.25 mm layer,
Merck). The chromatograms were visualized under UV light at 254 and 366 nm and with 10% H2 SO4
spray, then heated.
3.2. Plant Material
The stem bark of M. kerstingii was collected in May 2018 in Touboro, a locality of the North Region
of Cameroon, and a voucher specimen was deposited at the National Herbarium of Cameroon with
the registration number N6661/SRFCAM.
3.3. Extraction of M. kerstingii Stem Barks and Isolation of Specialized Metabolites
The air-dried and powdered stem bark of M. kerstingii (100 g) was sonicated in a mixture of
ethanol/H2 O (7:3) for 2 h. The mixture was filtered, and the solvent evaporated under reduced pressure
to give 13.20 g of a brownish crude extract (MKS). A total of 10 g of MKS was dissolved in H2 O and
partitioned successively using (3 × 50 mL) each of hexane (MKSHEX, 0.32 g) and ethyl acetate (MKSEA,
1.236 g) and n-butanol (MKSBUT, 7.55 g). Specialized metabolites 1–11 were isolated from M. kerstingii
roots as previously described [15].
3.4. Alkylation of Compound 1
In each experiment, 49.50 mg (0.15 mmol) of 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-4,7-dimethoxy-3methyl-2H-1-benzopyran-2-one 1 were added to anhydrous K2 CO3 (300 mg, 2.17 mmol, 15 eq) in dry
acetone (10 mL) followed by various alkylbromide as follows: (a) allylbromide (0.50 mL, d = 1.40,
0.70 g, 5.78 mmol); (b) propargylbromide (0.50 mL, d = 1.38, 0.69 g, 5.80 mmol); (c) prenylbromide
(0.50 mL, d = 1.29, 0.65 g, 4.33 mmol); (d) benzylbromide (0.50 mL, d = 1.44, 0.72 g, 4.21 mmol);
(e) p-bromobenzylbromide (d = 1.85, 0.20 g, 0.80 mmol). The reaction mixture was heated at 40 ◦ C
under reflux for 23 h. TLC was used to monitor the alkylation. At the end of the reaction, the solvent
was evaporated under reduced pressure. Each residue was suspended in water (40 mL) and then
extracted with ethyl acetate (60 mL). The extract was dried by anhydrous Na2 SO4 . The ethyl acetate
extract was then evaporated and purified through a silica gel column chromatography eluted with a
mixture n-hexane-ethyl acetate of increasing polarity. Moreover, further purifications of the synthesized
products were completed using the preparative TLC. Through this process, the semisynthetic derivatives
were obtained as follows: compound 1a (25.3 mg, 0.07 mmol, 46%, Rf 0.40, silica gel, hexane-EtOAc,
7:3 v/v); compound 1b (84.8 mg, 0.23 mmol, 90%, Rf 0.30, silica gel, hexane-EtOAc, 3:2 v/v); compound
1c (29.1 mg, 0.07 mmol, 49%, Rf 0.50, silica gel, hexane-EtOAc, 3:2 v/v); compound 1d (51.42 mg,
0.12 mmol, 82%, Rf 0.31, silica gel, hexane-EtOAc, 7:3 v/v); compound 1e (39.6 mg, 0.08 mmol, 53%,
Rf 0.43, silica gel, hexane-EtOAc, 4:1 v/v).
3.5. Antifungal Bioassay
Yeasts isolates. F. oxysporum strains Fo32931 and Fo4287 were obtained from Ma Lab (University
of Massachusetts-Amherst). The fungi were prepared from glycerol stocks. Each F. oxysporum strain
was first grown on potato dextrose agar (PDA) media by inoculating 20 µL of stock at the center of the
plate and incubating at 28 ◦ C for three days. Fungi were then transferred and grown in PDB for two
days. Spores were filtered using a miracloth, and 1 × 107 spores/mL concentration were obtained using
a hemocytometer.
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Preparation of stock solutions. M. kerstingii crude extract stock solution (MKS) was prepared at
20 mg/mL. Fractions (MKSHEX, MKSEA, and MKSBUT) and pure compound stock solutions were
prepared at 6 mg/mL, while nystatin at 1 mg/mL was used at positive control. Tested samples and
control were dissolved in 50% DMSO.
Growth curve and determination of the MIC. Serial dilutions were performed to achieve
concentrations ranging from 1000 to 31.25 µg/mL from extracts and fractions, and from 300 to
18.75 µg/mL for pure compounds. Samples were tested against 10% v/v of 1 × 107 spores/mL of
F. oxysporum in a 96 well plate at the final concentration of 1 × 106 spores/mL F. oxysporum in each
plate. Ten percent v/v of 1 × 107 spores/mL F. oxysporum was supplemented with PDB media to a
final volume of 200 µL. For the positive control, 5% v/v of nystatin stock at the final concentration
of 50 µg/mL was used. PDB was used as negative control. As F. oxysporum is sensitive to DMSO,
its concentration was maintained at 2.5% throughout the screenings. Experiments were performed in
duplicates and repeated three times for each experiment. The antifungal activities of crude extracts
fractions and pure compounds were assessed by the inhibition growth curve through a kinetic reading
of the optical density at 600 nm of the media over 24 h using a spectrophotometer (SpectraMax
M2 Multilabel Microplate Reader). After subtraction of the OD of the blank, which consisted of
non-inoculated wells that had been incubated together with the inoculated wells, from the OD of the
inoculated wells, the inhibition percentages were calculated as defined by Campbell in 2010 [42] as
Inhibition Percentage = 100 − [(ODavg sample − ODavg pos )/(ODavg neg − OD avg pos ) × 100]. The minimal
inhibitory concentration was determined by the lowest concentration of the sample achieving 100%
of inhibition [43] using a linear regression in the program GraphPad Prism version 5.00 (GraphPad
Software, San Diego, CA, USA) for Windows. The antifungal activity of the samples was analyzed
as active or not active according Morales et al.’s criteria: strong/good activity (MIC < 100 µg/mL);
moderate activity (100 < MIC < 500 µg/mL); weak activity (500 < MIC < 1000 µg/mL); no activity
(MIC >1000 µg/mL) [16].
4. Conclusions
This research was designed to evaluate the potential of M. kerstingii stem bark crude extracts,
fractions, natural metabolites from these fractions, and semisynthetic analogues of compound
1 against two multiresistant F. oxysporum strains (Fo32931, pathogenic to humans, and Fo4287,
pathogenic to plants). Results revealed that crude stem bark from M. kerstingii has a weak
activity against both strains. However, after fractionation, the n-butanol extract exhibited
strong activity against Fo4287, two times more than nystatin, the positive control. Results also
revealed that the stilbene–coumarin (1), as well as ellagic acid and its derivative (5 and 6) were
the most active principle of this plant. However, ellagic acid derivatives showed significant
activity only against Fo32931, whereas the stilbene–coumarin (1)—5-[(1E)-2-(4-hydroxyphenyl)
ethenyl]-4,7-dimethoxy-3-methyl-2H-1-benzopyran-2-one—was active against both strains. Compared
to the starting material 1, which had marginal strong activity against both strains, the semisynthetic
analogues were either only moderately active (against Fo2391) or inactive (against Fo4287),
demonstrating the importance of the phenolic group on antifungal activity. Only the prenylated
derivative 1c exhibited an activity comparable to compound 1 against Fo2391, highlighting the key role
of the prenyl group that is known to increase the antimicrobial activity of a molecule. In summary, this
study reveals that the n-butanol fraction of M. kerstingii and its phytoconstituents have potential as
natural environment-friendly fungi-toxicant against F. oxysporum. We identified stilbene–coumarin as
a promising lead compound that can be further explored for improved efficacy through synergism
with other compounds or further chemical transformations.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/9/537/s1,
Figures S1–S49.
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